A fire ripped through a garment factory here and spread to an adjoining pharmaceutical factory, prompting a major relief operation that lasted for more than eight hours and utilised services of over two dozen water tenders, officials said on Saturday. Chief Fire Officer (CFO) Pradeep Kumar said no one was injured in the incident that took place in B-Block of Sector 67. The fire service unit's control room received an alert call about the fire at 12 noon, he said. "We immediately sent eight vehicles to the spot but found that it was a major fire, which had spread from the garment factory to the adjoining pharmaceutical factory. This pharma factory was shut for the past two years but the items which were stocked inside caught the fire and intensified the blaze," Kumar said. "We had to deploy 28 vehicles and by 8.30 pm we were able to completely extinguish the fire. Fortunately, there was no injury to any person and no loss of life in the incident," the CFO said. Kumar said additiona
Companies must commit that they comply with a code against unethical marketing of drugs
The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.
Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions. The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement. The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2 per cent/0.5 per cent has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2 per cent/0.5 per cent of AbbVie, Inc, it added. The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added. Combigan ophthalmic solution, 0.2 per cent/0.5 per cent achieved annual sales of approximately USD 290 million, the company said citing IQVIATM sales data
The drug maker was reportedly interested in buying private equity (PE) firm Advent International's stake in Mumbai-based biopharma firm Bharat Serums and Vaccines (BSV)
It is estimated that more than 120 million people are living with chronic kidney disease in China
Peak XV Partners (formerly Sequoia India) has been invested in La Renon since 2015, with A91 Emerging Fund joining in 2021
MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas
An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales
A search conducted by Pharmarack showed that brands of any company, labelled under their mother brands, were observed to enjoy greater market share among their peers
With this agreement, India will become the first global territory where Centhaquin (Lyfaquin) is being launched immediately, according to the company
Collaboration aligns with Sanofi's growth strategy in India, named 'India for India', aims to accelerate growth across its pharmaceuticals, specialty care, consumer healthcare, and vaccines business
Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026
Gross margins improved by 313 basis points on a sequential basis to 60.7 per cent given lower raw material costs and improved product mix
The company's revenue from formulations increased by 17.2 per cent Y-o-Y to Rs 6,291 crore. Sequentially, it was up by 5.4 per cent from Rs 5,968 crore in Q2 FY24
The company reported a 13.7 per cent increase in sales to Rs 6,603 crore led by 11.5 per cent growth in the India business
Company reported lower-than-expected revenue after missing target in key segment
Indian drug firms are focussing on expanding their salesforce and distribution, while getting into trade generics to garner volumes
The report said that 28 per cent of healthcare and pharma companies had already implemented their first GenAI solutions
In the healthcare segment, hospitals are expected to post revenue growth of 13 percent during the coverage, while the net profit growth would be around 37 percent, ICICI Securities said in a note